Fields_2007_Curr.Opin.Anaesthesiol_20_307

PURPOSE OF REVIEW: Sugammadex is a novel drug that binds selected neuromuscular blocking drugs and prevents them from acting at the neuromuscular junction. Due to its rapid onset and relative lack of side effects, this drug promises to change the method of anesthesia delivery. This review summarizes the literature on the drug and addresses some of the potential changes that it may bring. RECENT FINDINGS: Currently in phase III clinical trials, sugammadex has been shown to be safe and efficacious in small animal and human study groups and is now undergoing wider clinical testing to secure FDA approval for general use. SUMMARY: Sugammadex binds neuromuscular blocking drugs and encapsulates them, making cholinesterase inhibitors unnecessary. Its rapid reversal of blockade makes it possible to keep patients profoundly muscle relaxed until drapes come down and it can enable a rapid return to spontaneous ventilation in a 'cannot intubate, cannot ventilate' situation. Costs and date of availability have yet to be determined.